RxDoctor Payments Data

Denis Jusufbegovic, MD

Retina Specialist · Carmel, INNPI 1952544975

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 4 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 4 manufacturers reported payments, led by Carl Zeiss Meditec, Inc. at 56.7% of the total. Reporting peaked in 2019 at $93 and has fallen 84.8% since, to $14 in 2023. That places this record below the midpoint for retina specialist clinicians in IN, where the typical reported total is $1,015.

$123in general payments, 2019–2025

Across 4 payments — averaging $30.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Carl Zeiss Meditec, Inc.$70
  • Novartis$23
  • AbbVie$16
  • Hologic Sales And Service, LLC$14
$7,688in research payments, 2019–2025

Across 17 payments — averaging $452.24 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Novo Nordisk AS$8K

What the payments were for

  • Food & beverage$123100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$123 in reported general payments places this provider in the 5th percentile of 21 retina specialist providers in Indiana.

See all retina specialist providers in Indiana

Medicare billing

Part B allowed, 2024
$416,365
Medicare patients
251
Services billed
4,986

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Prednisolone Acetate17$822
Latanoprost28$175
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat19$154
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha11$128

Paid to pharmacies, not to this prescriber.

Other retina specialist in Carmel

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →